Hexadecenoic Acid (Palmitoleic Acid): A Comprehensive Reference
1. Identity, Nomenclature, and Chemical Characterization
Hexadecenoic acid is the systematic class name for a family of 16-carbon monounsaturated fatty acids bearing a single carbon-carbon double bond. Within this family, the most abundant and most studied member is palmitoleic acid, or (9Z)-hexadec-9-enoic acid.
Palmitoleic acid, or (9Z)-hexadec-9-enoic acid, is an omega-7 monounsaturated fatty acid (16:1n-7) with the formula CH3(CH2)5CH=CH(CH2)7COOH. Its molecular weight is 254.41. It carries CAS registry number 373-49-9.
Other names and synonyms in common use include: cis-9-hexadecenoic acid; 9-hexadecenoic acid, (Z)-; cis-δ9-hexadecenoic acid; palmitolinoleic acid; 9-cis-hexadecenoic acid; (Z)-palmitoleic acid; and cis-hexadec-9-enoic acid.
Palmitoleic acid exists in two isomers, cis and trans. Although trans-palmitoleate is also synthesized in humans, it is mainly found as an exogenous source in ruminant fat and dairy products. The cis isomer (cis-16:1n-7) is the endogenously produced and more biologically prominent form. Positional isomers of hexadecenoic acid are considered fatty acids with anti-inflammatory properties. The best known of them, palmitoleic acid (cis-9-hexadecenoic acid, 16:1n-7), has been identified as a lipokine with important beneficial actions in metabolic diseases. Hypogeic acid (cis-7-hexadecenoic acid, 16:1n-9) has been regarded as a possible biomarker of foamy cell formation during atherosclerosis.
Palmitoleic acid (16:1n-7) and sapienic acid (16:1n-10) are synthesized from palmitic acid by the action of stearoyl-CoA desaturase-1 and fatty acid desaturase 2, respectively. A third positional isomer, hypogeic acid (16:1n-9), is produced from the partial β-oxidation of oleic acid.
In recent years, the monounsaturated hexadecenoic fatty acids are being increasingly considered as biomarkers of health with key functions in physiology and pathophysiology.
2. Natural Sources and Distribution
Palmitoleic acid is a rare component of fats. It is present in all tissues but, in general, is found in higher concentrations in the liver. It is biosynthesized from palmitic acid by the action of the enzyme delta-9 desaturase.
Palmitoleic acid is found in trace amounts in most foods except for sardine oil, which contains 15% of this acid as a component of triglycerides. Other dietary sources of palmitoleic acid include breast milk, a variety of animal fats, vegetable oils, and marine oils.
Food sources that naturally contain palmitoleic acid are limited and include certain blue-green algae, macadamia nuts (3.7 g/oz; 17% of fat content), and sea buckthorn oil extracted from the seed or berries of the plant.
Based on current knowledge, palmitoleic acid is found to be most abundant in the pulp of sea buckthorn, a deciduous shrub cultivated mainly in Asia, particularly in Northwest China. The percentage of palmitoleic acid in sea buckthorn pulp oil can vary by different growing areas and plucking times and could be as high as 42%.
Dietary sources with high palmitoleate content include salmon, cod liver oil, and macadamia oil (6%, 7%, and 17% or g/100 g total fatty acids, respectively). Currently, the highest reported concentration of palmitoleate in foods corresponds to the shrub sea buckthorn, which is native to Asia and Europe.
Of all fatty acid categories, monounsaturated fatty acids (MUFAs) are consumed the most, comprising 36% of total fat intake, and the majority of MUFA consumption is oleic acid at 27 g/day. Second to oleic acid is palmitoleic acid at 1.2 g/day. The average Western diet consists of approximately 2 grams of palmitoleic acid per day.
3. Biosynthesis and Endogenous Metabolism
Palmitoleic acid is biosynthesized from palmitic acid by the action of the enzyme Stearoyl-CoA desaturase-1 (SCD1). It is known that carbohydrate intake increases SCD1 expression, and therefore a direct relation between dietary carbohydrate and palmitoleate concentrations was expected. Various other studies in humans have also exposed a direct association between carbohydrate intake and plasma palmitoleate, indicating upregulation of de novo lipogenesis.
The cis isoform (cis-palmitoleate) is produced endogenously, while the trans isoform can be generated from dietary vaccenic acid. After synthesis, palmitoleic acid is incorporated into triglycerides, phospholipids, waxes, and cholesterol esters.
The bulk of hexadecenoic fatty acids found in mouse peritoneal macrophages is esterified in a unique phosphatidylcholine species, which contains palmitic acid at the sn-1 position and hexadecenoic acid at the sn-2 position. This species markedly decreases when the macrophages are activated with inflammatory stimuli, in parallel with net mobilization of free hexadecenoic acid.
While most of the released hexadecenoic acid accumulates in free fatty acid form, a significant part is also transferred to other phospholipids to form hexadecenoate-containing inositol phospholipids, which are known to possess growth-factor-like properties, and are also used to form fatty acid esters of hydroxy fatty acids, compounds with known anti-diabetic and anti-inflammatory properties.
4. Common Forms, Preparations, and Commercial Presentation
Palmitoleic acid is an unusual omega-7 monounsaturated fatty acid that occurs naturally in high levels in macadamia plants. Due to the potential health applications of palmitoleic acid, natural products such as macadamia nuts, in which palmitoleic acid is naturally abundant, may serve as an effective dietary source for this oil, or as a raw product for cosmetic or nutraceutical products.
The berries and seeds of sea buckthorn yield two distinct oils with different fatty acid profiles: the berry oil is rich in palmitoleic acid (omega-7) and carotenoids, while the seed oil is rich in alpha-linolenic acid (omega-3) and linoleic acid (omega-6). Plant sources are being used as food supplements (sea buckthorn fruit is used as "superfood") or premium food ingredients (macadamia nuts are used in chocolate and other high value foods) or in cosmetics (mink oil).
As a dietary supplement, palmitoleic acid concentrate oils are available commercially. According to an expert panel, 5 g POA/d (as 10 g of either Provinal® EE or TG) for the average user and 10 g POA/d (as 20 g of either Provinal® EE or TG) for a 90th percentile user is Generally Recognized as Safe (GRAS).
5. Traditional and Historical Use
The traditional use of palmitoleic acid as an isolated compound is not historically documented; rather, it was consumed as an integral component of plant and marine oils used in traditional medicine systems. The primary carrier of palmitoleic acid in traditional medicine has been sea buckthorn (Hippophae rhamnoides L.).
Hippophae rhamnoides L. (family Elaeagnaceae, common name sea buckthorn) is a flowering shrub native to cold-temperate regions of Eurasia. Berries, seeds, and leaves of the plant are widely used as a folk medicine for the treatment of hypertension, oedema, inflammation, tissue-regeneration, skin-grafts, burns/injury, wounds, and ulcers.
The plant has a long history of traditional use across Russia, China, Mongolia, and Scandinavia for wound healing, digestive support, and skin conditions. Historically utilized in ancient Chinese medicine, sea buckthorn is rich in vitamins C and A, as well as bioflavonoids and carotenoids, which are believed to offer various health benefits.
Sea buckthorn has been used for hundreds if not thousands of years in traditional medical applications, including for dermatological purposes. Among plants with documented medicinal use, sea buckthorn stands out as a phylogenetically ancient Elaeagnaceae species with a 200-million-year evolutionary history. Its medicinal use dates back centuries, with modern applications spanning pharmaceuticals, nutraceuticals, and cosmeceuticals.
Macadamia nuts (Macadamia integrifolia), another rich natural source of palmitoleic acid, have been a traditional food source for Indigenous Australians for millennia, though their consumption was not linked to the isolated fatty acid in any traditional therapeutic framework.
Marine sources such as sardine oil and cod liver oil, likewise containing palmitoleic acid, have historic use in traditional Northern European and coastal Asian diets for general health maintenance, skin integrity, and inflammatory ailments, though again palmitoleic acid was not isolated or recognized as the active constituent until modern biochemical research.
6. Active Constituents and Established Mechanisms of Action
6.1 The Lipokine Concept
Palmitoleic acid (cis-9-hexadecenoic acid, 16:1n-7) is the most abundant member of the hexadecenoic acid family and, likely because of this, the most studied. This isomer appears to have unique biological actions in modulating metabolic responses, which has led to the concept of it serving as a lipid hormone, or 'lipokine', that coordinates metabolic responses between tissues.
Release of this fatty acid from the adipose tissue acted to suppress steatosis in the liver and improve insulin signaling in muscle. Overall, the study suggested that 16:1n-7 exerts anti-inflammatory effects in the adipose tissue of mice that help mitigate the impact of obesity. Thus, 16:1n-7, but not palmitic acid, suppressed cytokine expression in adipocytes but not in stromal vascular cells, pointing to the former cells as the major target for 16:1n-7. The authors proposed that 16:1n-7 acted as a lipokine on the basis of: (i) its specific behavior during de novo lipogenesis, accumulating in adipose tissue instead of being a simple intermediate, and (ii) its extremely rapid fluctuation as a reflection of this lipogenesis.
6.2 Insulin Sensitization and Pancreatic Beta-Cell Effects
Palmitoleic acid was described as a lipokine able to regulate different metabolic processes such as an increase in insulin sensitivity in muscle, β cell proliferation, prevention of endoplasmic reticulum stress, and lipogenic activity in white adipocytes.
Studies utilizing high fat diet (HFD)-fed mice revealed that 16:1n-7 administration improves the whole-body insulin sensitivity and glucose uptake into adipose tissue through the regulation of GLUT-4 and AMPK phosphorylation. 16:1n-7 increased lipolysis and enhanced the expression levels of Atgl and Hsl in adipocytes by a mechanism requiring a functional PPARα.
Palmitoleic acid (POA) is a nonessential, monounsaturated omega-7 fatty acid (C16:1n7), described as a lipid hormone secreted from adipose tissue with beneficial effects on distant organs, such as the liver and muscle. Interestingly, POA decreases lipogenesis in toxic storage sites such as the liver and muscle, and paradoxically increases lipogenesis in safe storage sites, such as adipose tissue. Furthermore, higher POA levels in humans are correlated with better insulin sensitivity, an improved lipid profile, and a lower incidence of type-2 diabetes and cardiovascular pathologies, such as myocardial infarction.
6.3 Anti-inflammatory Mechanisms
Palmitoleic acid modified TNF-α, IL-1β, IL-6, CINC-2α/β, MIP-3α, and VEGF-α profiles at wound sites. Assays assessing neutrophil migration and exudate formation revealed that palmitoleic acid had potent anti-inflammatory activity, inhibiting LPS-induced release of TNF-α (73.14%, p≤0.05), IL-1β (66.19%, p≤0.001), and IL-6 (75.19%, p≤0.001).
Supplementation of palmitoleate decreased the phosphorylation of nuclear factor kappa B (NF-κB, p65) and the expression of proinflammatory cytokines. Palmitoleate also decreased the phosphorylation of NF-κB p65 and the expression of proinflammatory cytokines in cultured macrophages.
POA activates basal lipolysis and reesterification, elevates Lpl activity, modulates n3-PUFA metabolism in membrane phospholipids, and markedly affects pro- and anti-inflammatory cytokine production by epididymal adipose tissue (EAT). Thus, POA acts as a lipokine capable of influencing and modulating metabolic processes in adipose and other peripheral tissues by altering cytokine secretion and modulating circulating NEFA profiles.
6.4 Lipid Metabolism and Hepatic Effects
In terms of regulating fatty acid synthase (FAS) expression, treatment of palmitoleate increased the transcription activity of SREBP1c and enhanced the binding of SREBP1c to FAS promoter. This dual action — suppressing liver inflammation while increasing hepatic lipogenic gene activity — is one of the most debated aspects of palmitoleic acid's biology.
6.5 Skin and Antimicrobial Mechanisms
Experimental and preclinical topical evidence suggests palmitoleic acid (POA) has antimicrobial effects, enhanced lubrication properties, protection from oxidative and ultraviolet B (UVB) injury, and enhanced wound repair capabilities.
Both POA and sapienic acid reduce adhesion of the yeast Candida albicans to the stratum corneum, suggesting a role in enhancing barrier resilience against opportunistic pathogens. An important extension of this antimicrobial profile is the observation that POA exhibits a synergistic killing effect when combined with low concentrations of ethanol. This combination produces rapid and pronounced reductions in viable counts of Staphylococcus aureus, including methicillin-resistant strains, as well as of typically more resistant Gram-negative species such as Pseudomonas aeruginosa and Cutibacterium acnes.
7. Scientific Evidence by Area of Use
7.1 Insulin Resistance and Type 2 Diabetes
Observational and epidemiological evidence (human): In a prospective cohort of 3,630 US men and women in the Cardiovascular Health Study (CHS), plasma phospholipid fatty acids, anthropometric variables, blood lipids, inflammatory markers, and glucose and insulin concentrations were measured between 1992 and 2006, investigating whether palmitoleate is related to lower metabolic risk and the incidence of diabetes.
Consistent with animal studies, human studies have shown that higher POA is correlated with lower insulin resistance, diabetes incidence, dyslipidemia, hypertension, atherosclerosis, and myocardial infarction. The positive association studies were followed by an extensive meta-analysis of 16 multicentric prospective cohort studies. The meta-analysis showed that higher levels of POA were associated with a lower risk of developing type 2 diabetes.
Experimental studies suggest that the fatty acid palmitoleate may act as an adipocyte-derived lipid hormone (or 'lipokine') to regulate systemic metabolism. Plasma NEFA concentration and composition were determined in non-diabetic individuals from the Relationship between Insulin Sensitivity and Cardiovascular disease (RISC) study cohort at baseline (n = 1,234) and after a 3-year follow-up (n = 924). This analysis described, for the first time, a cross-sectional positive relationship between palmitoleate and beta cell function in humans, with potential differences between men and women. This finding is consistent with previous studies in pancreatic islets and isolated beta cells, which exhibited increased basal and glucose-stimulated insulin secretion and were protected from apoptosis when exposed to palmitoleate. Despite this evidence, the lack of a significant association between changes in palmitoleate and beta cell function over time warrants cautious interpretation of this finding and confirmation by intervention studies.
Important caveat: Although dietary fatty acids can modulate metabolic and immune responses, the effects of palmitoleic acid (16:1n-7) remain unclear. Since this monounsaturated fatty acid is described as a lipokine, studies with cell culture and rodent models have suggested it enhances whole body insulin sensitivity, stimulates insulin secretion by β cells, increases hepatic fatty acid oxidation, improves the blood lipid profile, and alters macrophage differentiation. However, human studies report elevated blood levels of palmitoleic acid in people with obesity and metabolic syndrome. This paradox — where higher circulating levels associate with both improved metabolic parameters in some studies and with obesity and metabolic syndrome in others — reflects the complex role of endogenous vs. exogenous sources.
Interventional evidence (human): A double-blind placebo-controlled clinical trial tests the hypothesis that POA increases insulin sensitivity and decreases hepatic lipogenesis in overweight and obese adult subjects with pre-diabetes. Notably, this is the first study to use pure (>90%) POA with <0.3% palmitic acid, which masks the beneficial effects of POA. Evidence strength for interventional human studies specifically on isolated palmitoleic acid supplementation remains preliminary as of the most recent literature.
7.2 Cardiovascular Health and Lipid Profile
Epidemiological studies suggest that circulating palmitoleate is involved in cholesterol metabolism and hemostasis, although net cardiovascular effects are not yet clear. In the Cardiovascular Health Study (CHS) cohort, plasma phospholipid palmitoleate was associated with lower LDL cholesterol and fibrinogen and higher HDL.
Palmitoleic acid (palmitoleate; C16:1 n-7), an omega-7 monounsaturated fatty acid found in plants and marine sources, has been shown to favorably modulate lipid and glucose metabolism. Its impact, however, on atherosclerosis has not been examined in detail. In a mouse model study, LDLR-KO mice were fed a Western diet supplemented with 5% (w/w) palmitoleate concentrate, oleic-rich olive oil, or none (control) for 12 weeks. Dietary palmitoleate increased hepatic C16:1 levels, improved plasma and hepatic lipid/lipoprotein profiles (~40% decrease in triglycerides), and reduced the atherosclerotic plaque area by ~45% compared with control or olive oil group (p<0.05). This is animal evidence only.
Other reports found no relation between plasma palmitoleic acids and coronary heart disease or diabetes. Results have shown mixed cardiovascular effects, direct or inverse correlations with obesity and hepatosteatosis, but a significant amelioration or prevention of insulin resistance and diabetes.
In various studies, but not all, the consumption of macadamia nuts (which contain high cis-palmitoleate concentrations) was related to favorable serum lipid profiles. Overall, contrasting results in humans could be due to heterogeneous populations, which include healthy subjects and patients with pre-existing dyslipidemia. Apparently, healthy subjects have no metabolic advantages with increased circulating palmitoleate, whereas supplementation in dyslipidemic subjects could be a strategy for the improvement of the serum lipid profile, although further research is needed to support this statement.
Overall, while there is scientific rationale and some early data supporting palmitoleic acid's potential cardiovascular benefits, the quality and quantity of evidence are not yet strong. Larger, long-term clinical trials are needed to establish its efficacy and safety in preventing or treating cardiovascular disease. Current scientific support is modest.
7.3 Trans-Palmitoleate and Metabolic Risk
The trans isomer of hexadecenoic acid has been studied as a distinct biomarker. Whereas trans-fats from partially hydrogenated oils unfavorably affect cardiovascular risk, trans-palmitoleate is principally derived from naturally-occurring dairy/ruminant trans-fats, consumption of which has not been associated with higher cardiovascular risk. Palmitoleic acid (cis-16:1n-7), produced by endogenous fat synthesis, has been linked to both beneficial and deleterious metabolic effects, potentially confounded by diverse determinants and tissue sources of endogenous production. Trans-palmitoleate (trans-16:1n-7) represents a distinctly exogenous source of 16:1n-7, unconfounded by endogenous synthesis or its determinants, that may be uniquely informative.
Several cohorts have seen inverse associations between dairy consumption and risk of insulin resistance, metabolic syndrome, and diabetes. The consumption of trans-palmitoleate from dairy was associated with lower amounts of inflammation, but mixed relations with serum lipids.
7.4 Non-Alcoholic Fatty Liver Disease (NAFLD)
The role of palmitoleic acid in NAFLD is complex and currently controversial. The role of palmitoleate in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is controversial.
On one hand, results in mouse studies suggest that palmitoleate acts through dissociating liver inflammatory response from hepatic steatosis to play a unique role in NAFLD. On the other hand, other studies showed that hepatic steatosis was caused by palmitoleate in mice, even though liver inflammation was attenuated. In rats fed sucrose, which is typically associated with the development of NASH, palmitoleic acid was increased in the plasma and liver. In humans, plasma palmitoleate was found to be increased in patients with either NAFLD or NASH.
Evidence in this area is predominantly from animal models and observational human data. The direction of causality between elevated circulating palmitoleate and NAFLD in humans — whether palmitoleate is a driver or a marker — has not been established by controlled clinical trials.
7.5 Wound Healing and Skin Health (Topical Use)
A study investigated the effects of palmitoleic acid on different phases of the healing process. Macroscopic analyses were performed on wounds in rats with or without palmitoleic acid treatment, and the results showed that palmitoleic acid directly hastened wound closure. The topical treatment of wounds with palmitoleic acid resulted in smaller wounds than those observed in the control group. The anti-inflammatory activity of palmitoleic acid may be responsible for healing, especially in the stages of granulation tissue formation and remodelling.
In a clinical study involving sea buckthorn oil, Wang and colleagues reported on using H. rhamnoides oil, a traditional Chinese herbal medicine derived from sea buckthorn fruit, as a burn treatment. In the study, 151 burn patients received an H. rhamnoides oil dressing (changed every other day until wound healing). The dressing reduced swelling and effusion and alleviated pain, with patients receiving the sea buckthorn dressing experiencing greater apparent exudation reduction, pain reduction, and more rapid epithelial cell growth and wound healing than controls (treated only with Vaseline gauze). The difference between the two groups was statistically significant.
Pharmacological studies demonstrated sea buckthorn to exhibit antibacterial, anti-sebum, antifungal, anti-psoriasis, anti-atopic dermatitis and wound healing activities. However, it is important to note that these studies were conducted with whole sea buckthorn oil containing multiple bioactive components, not isolated palmitoleic acid. Attributing the effects exclusively to palmitoleic acid is not possible from the available evidence.
Findings collectively demonstrate that sea buckthorn components, including fatty acids, flavones, and leaf extracts, enhance skin repair through multiple mechanisms, including cell proliferation, collagen deposition, antioxidant activity, and angiogenesis.
7.6 Hypertension
Preclinical evidence suggests palmitoleic acid may protect against hypertension. A 2021 study referenced in clinical trial databases found that palmitoleic acid protects against hypertension by inhibiting NF-κB-mediated inflammation (Mol Nutr Food Res, 2021). This evidence is currently limited to animal models; robust human clinical trial data specifically on palmitoleic acid and blood pressure are lacking.
7.7 Inflammation (Systemic and Local)
Results in animal prediabetes models show that POA served as a lipokine, ameliorating insulin sensitivity in peripheral tissue and markedly modulating the metabolic activity of visceral adipose tissue (VAT) including cytokine secretion. The mechanism of improved insulin sensitivity in POA-treated rats could reflect increased circulating adiponectin and omentin levels together with elevated FADS1 gene expression in VAT. POA-supplemented rats exhibited markedly decreased proinflammatory cytokine production by VAT, which can alleviate chronic inflammation.
Human clinical trial evidence specifically targeting systemic inflammation using isolated palmitoleic acid supplementation remains limited. A registered clinical trial (NCT03625427) has tested 500 mg and 1,000 mg/day doses of palmitoleic acid against placebo for effects on C-reactive protein over 12 weeks; published results from this trial were not available in the sources retrieved.
7.8 Cancer
The current knowledge of the effects of palmitoleic acid on cancer has been reviewed alongside metabolic diseases, with results showing diverse effects among studies in cell lines, animal models, and humans. The evidence is at the in vitro and early preclinical stage. Human clinical evidence on palmitoleic acid as an anticancer intervention does not yet exist in the published literature.
8. Body Systems and Health Areas of Association
- Endocrine/Metabolic system: Cell culture and rodent models suggest palmitoleic acid enhances whole body insulin sensitivity, stimulates insulin secretion by β cells, increases hepatic fatty acid oxidation, improves the blood lipid profile, and alters macrophage differentiation.
- Cardiovascular system: Epidemiological studies suggest that circulating palmitoleate is involved in cholesterol metabolism and hemostasis, although net cardiovascular effects are not yet clear.
- Hepatic system: The role of palmitoleate in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is controversial.
- Immune/Inflammatory system: Palmitoleic acid has been found to have anti-inflammatory effects, decreasing inflammation.
- Integumentary system (skin): Hexadecenoic acid isomers influence membrane packing, modulate the fluidity of intercellular lipid lamellae, and contribute to the antimicrobial and immune-modulatory functions of the skin surface lipid film.
- Adipose tissue (endocrine signaling): Relative release of palmitoleate was higher than that of other fatty acids, and its release from gluteofemoral adipose tissue was increased compared with that of abdominal adipose tissue, mainly because of greater tissue abundance. If palmitoleate is readily mobilized from peripheral subcutaneous adipose tissue, then its role as a lipokine would be consistent with the insulin-sensitizing action of peripheral fat.
9. Dosage Forms and Dosages Reported in Studies
There is currently no established recommended daily intake for palmitoleic acid. Currently, there is no recommended human daily intake of palmitoleate.
The following dosages have been specifically reported in research contexts:
- Human intervention studies have documented the consumption of up to 15.3 g of POA/day for a duration of up to four weeks, with no serious adverse effects reported.
- According to an expert panel, 5 g POA/d (as 10 g of either Provinal® EE or TG) for the average user and 10 g POA/d (as 20 g of either Provinal® EE or TG) for a 90th percentile user is Generally Recognized as Safe (GRAS).
- In a registered placebo-controlled clinical trial, 1,512 mg of pure palmitoleic acid was given to the treatment arm.
- A registered clinical trial (NCT03625427) tested palmitoleic acid at 500 mg/day (Dose 1: one 1-gram capsule containing 500 mg POA per day for 12 weeks) and at 1,000 mg/day (Dose 2: two 1-gram capsules containing 500 mg POA each, totaling 1,000 mg POA per day for 12 weeks).
- In a rat prediabetes model, POA was administered intragastrically at a dose of 100 mg/kg body weight for four weeks.
- In a mouse atherosclerosis study, palmitoleate supplementation was calculated to produce a human (70 kg) equivalent dose of 13 g/day of palmitoleate.
10. Safety Considerations and Interactions
10.1 General Safety Profile
Human intervention studies have documented the consumption of up to 15.3 g of POA/day for a duration of up to four weeks, with no serious adverse effects reported. The long-term safety of supplemental palmitoleic acid has not been established in rigorous controlled trials.
10.2 Palmitic Acid Contamination as a Confounding Safety Issue
Most commercial preparations that have been studied contain significant amounts of palmitic acid, a saturated fatty acid that masks the beneficial effects of POA. Because palmitic acid has established adverse effects on cellular viability and metabolic health, the purity of a palmitoleic acid supplement is a scientifically important variable that affects both observed efficacy and potential risk. Preparations with high palmitic acid content may negate or obscure the biological effects of palmitoleic acid.
10.3 The Paradox of Elevated Circulating Levels
Human studies report elevated blood levels of palmitoleic acid in people with obesity and metabolic syndrome. The extent to which such findings might be confounded by carbohydrate or calorie consumption driving hepatic fat synthesis and weight gain was not assessed in many of these studies. Taken together, these results highlight the challenges in linking steady-state palmitoleate concentrations to metabolic effects in humans because of the likely dominance of hepatic fatty acid synthesis and its complex determinants.
10.4 Hepatic Lipid Accumulation
Palmitoleate supplementation increased the circulating levels of palmitoleate and improved systemic insulin sensitivity. Locally, however, hepatic fat deposition and SREBP1c and FAS expression were significantly increased in palmitoleate-supplemented mice. This finding — that palmitoleate may paradoxically increase hepatic lipid accumulation even while improving systemic insulin sensitivity — is a key safety-relevant observation that requires clarification in human trials.
10.5 Trans-Palmitoleate and Cardiovascular Risk
Whereas trans-fats from partially hydrogenated oils unfavorably affect cardiovascular risk, trans-palmitoleate is principally derived from naturally-occurring dairy/ruminant trans-fats, consumption of which has not been associated with higher cardiovascular risk. This distinguishes naturally occurring trans-palmitoleate from industrially produced trans fats.
10.6 SCD1 Enzyme Activity and Metabolic State
It is known that carbohydrate intake increases SCD1 expression, and therefore a direct relation between dietary carbohydrate and palmitoleate concentrations was expected. In subjects with high carbohydrate intake, additional supplemental palmitoleic acid may compound hepatic lipogenic activity driven by already elevated SCD1 activity. This interaction has not been assessed in controlled human trials.
10.7 Evidence Limitations and Outstanding Uncertainties
Numerous beneficial effects have been attributed to palmitoleic acid, both in mouse models and in cell lines. However, its role in humans is not fully understood, and is sometimes controversial. Contrasting results in humans could be due to heterogeneous populations, which include healthy subjects and patients with pre-existing dyslipidemia.
No documented drug interactions specific to palmitoleic acid were identified in the peer-reviewed sources consulted. Given its role as a PPAR-α ligand and its influence on lipid metabolism, pharmacological interactions with lipid-lowering agents (e.g., statins, fibrates) and insulin sensitizers (e.g., thiazolidinediones) are biologically plausible but have not been evaluated in published human studies.
References
Go back